Riskpilot← Back to searchSign inGet full accessLimulus Bio AB
ABDissolvedOrg 5592337314Research and experimental development on biotechnology · NACE 7211Est. 20194 employees
Revenue 2022
SEK 12,6M
+121% vs 2021
EBITDA margin
10.1%
+284% vs 2021
Equity ratio
22.8%
Financial strength
Net profit 2022
SEK 1M
+221% vs 2021
| Revenue | SEK 12,6M | +121% |
| EBITDA | SEK 1,3M | +284% |
| Net profit | SEK 1M | +221% |
| Total assets | SEK 4,9M | +107% |
| Equity | SEK 1,1M | +117% |
| Employees | 4 | — |
Legal name
Limulus Bio AB
Org number
5592337314
Legal form
Aktiebolag
NACE code
7211 · Research and experimental development on biotechnology
Founded
20 december 2019
Share capital
SEK 50 000
Employees
4 (FTE)
VAT registered
No
Audit selected
No
Last report
2022-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas ensam av Dockhorn, David Wilke Firman tecknas i förening av Dockhorn, David Wilke Liljensten, Elisabeth Linnéa
Company purpose
Föremålet för bolagets verksamhet är att bedriva bioteknisk forskning och utveckling samt därmed förenlig verksamhet.
Address
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 |
|---|---|---|---|
| Revenue | 1 026 | 5 713 | 12 612 |
| Staff expenses | — | — | — |
| EBITDA | −444 | 331 | 1 270 |
| Depreciation & amort. | −3 | −7 | −7 |
| EBIT | −447 | 324 | 1 263 |
| Net financials | — | −12 | — |
| Profit before tax | −447 | 312 | 1 263 |
| Tax | −0 | −0 | −261 |
| Net profit | −447 | 312 | 1 002 |
| Item | 2020 | 2021 | 2022 |
|---|---|---|---|
| Total assets | 1 290 | 2 369 | 4 903 |
| Equity | 203 | 515 | 1 117 |
| Long-term debt | 0 | 0 | 0 |
| Short-term debt | 1 086 | 1 854 | 3 786 |
| Total debt | 1 086 | 1 854 | 3 786 |
EBITDA margin
10.1%
This company
15.8%
Market median
-36% vs market
20202022
Equity ratio
22.8%
This company
38.2%
Market median
-40% vs market
20202022
Return on equity
89.7%
This company
18.4%
Market median
+388% vs market
20202022
Net profit margin
7.9%
This company
8.1%
Market median
-2% vs market
20202022
Asset turnover
2.57×
This company
1.12×
Market median
+129% vs market
20202022
Debt / equity
3.39×
This company
0.62×
Market median
-447% vs market
20202022
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
MF Chief Auditor | Chief Auditor | 2020 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Deputy Board Member | 2022 | |
| Board of Directors | 2020 | |
| Chairman | 2022 | |
| Former (5) | ||
| Chairman | 2020 – 2020 | |
| Board of Directors | 2020 – 2020 | |
| Deputy Board Member | 2020 – 2020 | |
| Deputy Board Member | 2020 – 2020 | |
| Deputy Board Member | 2022 – 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Limulus Bio AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Magnus Fjellman | Chief Auditor | 0 companies |
| Elisabeth Linnéa Liljensten | Deputy Board Member | 0 companies |
| M H Charlotte Wiberg Larsson | Chairman | 0 companies |
| Bo Torsten Nilsson | Board of Directors | 0 companies |
| Peter Jonas Michael Carlborg | Deputy Board Member | 0 companies |
| Åsa Helena Runnäs | Board of Directors | 0 companies |
| David Wilke Dockhorn | Chairman | 0 companies |
| Bo Torsten Patrik Nilsson | Deputy Board Member | 0 companies |
| David Erik Liljensten | Deputy Board Member | 0 companies |